吉贝尔上半年归母净利润增长22% 多款新药取得阶段性成果

Financial Performance - Company reported a revenue of 455 million yuan for the first half of the year, representing a year-on-year growth of 4.90% [1] - Net profit attributable to shareholders reached 149 million yuan, with a year-on-year increase of 22.38% [1] - Company announced a cash dividend of 2.60 yuan per 10 shares for 2024, totaling 51.85 million yuan, reflecting strong profitability and commitment to shareholders [1] Product Performance - The sales of the product "Niqinluo Tablets" grew significantly, achieving a revenue of 91.04 million yuan, a year-on-year increase of 38.31%, becoming a key driver for revenue growth [2] - The product is recognized as the first fixed-dose combination of calcium channel blockers and beta-blockers in China, enhancing patient compliance and expanding the applicable population [2][3] - Another core product, "Likujun Tablets," is expected to drive future revenue growth, especially in oncology, due to its dual effects of prevention and treatment [3] R&D Progress - Company has made significant advancements in new drug development, with a focus on innovative drug research and a growing R&D team, increasing from 107 to 130 personnel [4] - The antidepressant drug JJH201501 has shown promising results in clinical trials, demonstrating significant efficacy and safety, and has completed phase III clinical enrollment [4] - The anti-tumor drug JJH201601 is progressing well in clinical trials, showing superior efficacy compared to existing treatments and good safety profiles [5][6] Market Environment - The domestic innovative drug policy environment has been improving, providing favorable opportunities for the development of innovative pharmaceutical companies [6] - With a solid product foundation, efficient marketing system, and a rich pipeline of R&D projects, the company is well-positioned to strengthen its competitive advantage and achieve sustained growth [6]